Abrocitinib

Status:: Red
Decision Date:: March 2021

Comments

RED:

NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. (Decision date - September 2022)

Adults commissioned by ICB. Adolescents commissioned by NHSE.